Calliditas Therapeutics: First patient randomized in pivotal

STOCKHOLM, Feb. 15, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the first patient has been randomized in the company's

Related Keywords

Sweden , Stockholm , Marie Galay , Exchange Commission , Trial Press , European Medicines Agency , Nasdaq Stockholm , Track Designation , Nasdaq Global Select Market , Kidney Disease , Private Securities Litigation Reform Act , Patient Randomized , Calliditas , Herapeutics , First , Patient , Randomized , Pivotal , Ransform , Study , Setanaxib ,